What does it mean when two natural compounds are both effective therapies for two seemingly distinct diseases. Curcumin and Optimized Resveratrol are both effective in killing multiple myeloma, my cancer. The study linked and excerpted below talk about curcumin and Optimized Resveratrol ‘s ability to also treat Alzheimer’s Disease (AD). And these two chronic, incurable diseases are not the only diseases that Curcumin and Optimized Resveratrol treat.
“Curcumin as nutritional supplement may help treat cancer, inflammation, ulcerative colitis, rheumatoid arthritis, osteo arthritis, diabetes, depression, anxiety, cognitive function and fatigue, chronic anterior uveitis and other conditions.”
“Resveratrol supplementation may treat cancer, may lower bad cholesterol, may reduce levels of inflammation, improves insulin sensitivity in diabetics, may help memory function and may help prevent the onset of Alzheimer’s Disease dementia and other neurodegenerative disorders.”
I am a long-term survivor of an incurable cancer and cancer coach. For more information about natural supplementation to treat Alzheimer’s Disease, scroll down the page, post a question or comment and I will reply ASAP.
“Alzheimer disease (AD) is by far the most common cause of dementia globally. This neurodegenerative disorder of the brain is chronic and progressive, characterized clinically by the deterioration in the key symptoms of behavioral and cognitive abilities…
Treatment options for this disease currently are limited…
In addition to mounting research on herbal compounds for the treatment of AD, curcuminoids and resveratrol appear to be beneficial as anti-AD agents…
This review article revisits and presents the current research done on the potential of the curcuminoids curcumin and demethoxycurcumin and the polyphenolic compound resveratrol as anti-AD compounds.”
There is limited choice in modern Alzheimer’s Disease therapeutics, and drugs available have limited success with multiple side effects in addition to high cost…
There are distinct similarities between my cancer, multiple myeloma and Alzheimer’s Disease. Both are incurable. Both have few effective conventional treatments. What conventional therapies there are cause harmful side effects and are expensive. Curcumin supplementation is a nutriceutical that is effective for both myeloma and AD, causes little collateral damage and is inexpensive.
So why don’t oncologists and neurologists prescribe Curcumin to their patients??? Why hasn’t the Food and Drug Administration approved Curcumin for Multiple Myeloma and Alzheimer’s Disease? My guess is that pharmaceutical companies won’t pay for studies for products that can’t be patented.
The brand of Curcumin that I take is Life Extension Super Bio Curcumin . This formulation has shown the ability to absorb into the blood stream better than other brands. I recommend LE Super Bio Curcumin .
For more information about nutritional supplementation and chronic disease, scroll down the page, post a question or a comment and I will reply ASAP.
“Alzheimer’s disease (AD) is the most common form of dementia. There is limited choice in modern therapeutics, and drugs available have limited success with multiple side effects in addition to high cost…
Hence, newer and alternate treatment options are being explored for effective and safer therapeutic targets to address AD…
Turmeric possesses multiple medicinal uses including treatment for AD. Curcuminoids, a mixture of CU, demethoxycurcumin, and bisdemethoxycurcumin, are vital constituents of turmeric.
The progress in understanding the disease etiology demands a multiple-site-targeted therapy, and the curcuminoid mixture of all components, each with different merits, makes this mixture more promising in combating the challenging disease.”
“Based on a review of these studies, it is evident that better bioavailability of formulated curcumin (CU) products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism”
A search of the Pubmed database for the word curcumin yields 601 studies spanning health topics from multiple myeloma (MM) and colorectal cancer, to chemotherapy regimens that integrate with CU, to Alzheimer’s Disease, arthritis and more. Based on years of reading studies and personal accounts, I think it is safe to say that CU supplementation is safe and relatively inexpensive and effective.
I have read posts about myeloma patients taking daily doses of CU from 400 milligrams to 8 grams (1000 milligrams = 1 gram). By almost any measure, CU is a safe, inexpensive wonder drug.
The only challenge is that CU is famously difficult to absorb in the body. In other words, a person has to mix curcumin with some sort of fat (coconut oil, chocolate, etc.) or take a brand of curcumin capsule that is already formulated to be more “bioavailable” in order to derive the full benefit of CU.
The study linked and exerpted below reviews different formulations of CU. The study itself lists the three most bioavailable formulation/brand of CU and I’ve added an excerpt from a further review from Consumerlab.com that lists four additional bioavailable brands of CU.
I consult the independent evaluation service Consumerlab.com frequently. For one low annual payment, I can read about and evaluate all of the nutritional supplements that I take.
Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.
The challenge for every myeloma patient is to achieve the deepest, longest remission possible while sustaining the least amount of collateral damage (side effects) possible. Numerous studies document the anti-MM and integrative efficacy of curcumin.
This link is to the Google search page for “curcumin in myeloma.” Whether it is an article authored by Pat Killingsworth or Margaret from Margaret’s Corner, or PubMed, curcumin is documented to be both cytotoxic to myeloma in addition to being “integrative” or enhancing the action of Velcade, Revlimid, and Thalidomide.
A common question asked by multiple myeloma patients considering supplementing with curcumin is about the daily dose. Unfortunately, I have several possible answers:
“CU is a bright yellow chemical produced by some plants. It is the principal curcuminoid of turmeric (Curcuma longa), a member of the ginger family, Zingiberaceae. It is sold as an herbal supplement, cosmetics ingredient, food flavoring, and food coloring.“
“Are you looking for a way to boost every facet of your health with a single spice? It sounds crazy, but turmeric curcumin with BioPerine may be the magic supplement we’ve been seeking. Turmeric benefits the body and mind in more ways than you can imagine. Similar to bone broth, turmeric impacts almost every facet of life. Over 10,000 peer-reviewed and clinical studies support using turmeric for better health…”
“Curcumin is a widely studied natural compound which has shown tremendous in vitro therapeutic potential. Despite that, the clinical efficacy of the native CU is weak due to its low bioavailability and high metabolism in the gastrointestinal tract. During the last decade, researchers have come up with different formulations with a focus on improving the bioavailability of curcumin. As a result, a significant number of bioavailable curcumin-based formulations were introduced with the varying range of enhanced bioavailability.
The purpose of this review is to collate the published clinical studies of CU products with improved bioavailability over conventional (unformulated) CU. Based on the literature search, 11 curcumin formulations with available human bioavailability and pharmacokinetics data were included in this review. Further, the data on clinical study design, analytical method, pharmacokinetic parameters and other relevant details of each formulation were extracted.
Based on a review of these studies, it is evident that better bioavailability of formulated curcumin products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism. The review hopes to provide a quick reference guide for anyone looking information on these bioavailable curcumin formulations.
Based on the published reports,
exhibited over 100-fold higher bioavailability relative to reference unformulated CU. Suggested mechanisms accounting for improved bioavailability of the formulations and details on the bioanalysis methods are also discussed.”
According to Consumerlab.com:
“Novasol has the highest bioavailability (185 x compared to unforumulated CU), followed by Curcuwin (136 x), Longvida (100 x), Meriva (48 x), BCM-95 (27 x), Curcumin C3 Complex + Bioperene (20 x), and then Theracumin (16 x).”
To confuse things even more, many brands of curcumin are more bioavailable than others. Bioavailability means absorption in the blood stream. Bioprene is known to enhance the bioavailability of curcumin.
Background: CU, the active component of the Curcuma longa plant, has been shown to potentiate the effect of the immunomodulatory drugs (IMiDs) thalidomide and Bortezomib against human myeloma cell lines and a nude mice model…
Conclusion: CU exerts a cytotoxic effect additive to that of lenalidomide on H929 myeloma cells, and it also enhances the chemo-sensitizing effects of this agent.
“Multiple myeloma (MM), a plasma cell malignancy, remains incurable despite the development of new therapies. CU anti-tumor effects were previously characterized in multiple myeloma, however only few MM cell lines were included in these studies.
Since myeloma is a heterogeneous disease it is important to address the impact of myeloma molecular heterogeneity in CU cell death induction.
In the present study, a large panel of human myeloma cell lines (HMCLs) (n = 29), representing the main molecular MM subgroups, was screened for CU sensitivity. We observed that CU cell death induction was heterogeneous, of note 16 HMCLs were highly sensitive to CU (LD50 < 20.5 μM), 6 HMCLs exhibited intermediate LD50 values (20.5 μM ≤ LD50 < 32.2 μM) and only 7 HMCLs were weakly sensitive (35 < LD50 < 56 μM).
Cell lines harboring the t(11;14) translocation were less sensitive (median LD50 32.9 μM) than non-t(11;14) (median LD50 17.9 μM), which included poor prognosis t(4;14) and t(14;16) cells.
Interestingly, CU sensitivity was not dependent on TP53 status. For the first time we showed that primary myeloma cells were also sensitive, even those displaying del(17p), another poor prognosis factor. We also unravel the contribution of anti-apoptotic Bcl-2 family molecules in CU response.
We found that down-regulation of Mcl-1, an essential MM survival factor, was associated with CU-induced cell death and its knockdown sensitized myeloma cells to CU, highlighting Mcl-1 as an important target for CU-induced apoptosis. Altogether, these results support clinical trials including CU in association with standard therapy.”